The use of fluorescence resonance energy transfer (FRET) peptides for measurement of clinically important proteolytic enzymes

Anais da Academia Brasileira de Ciencias

Volumn 81, Issue 3, 2009, Pages 381-392

  Carmona, Adriana K ^a   Juliano, Maria Aparecida ^a   Juliano, Luiz ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angiotensin I converting enzyme; Continuous recording assay; Fluorescence resonance energy transfer; FRET substrates; Neprilisin; Proteolytic enzymes

Indexed keywords

EID: 70349303457     PISSN: 00013765     EISSN: 16782690     Source Type: Journal    
DOI: 10.1590/s0001-37652009000300005     Document Type: Review

References (64)

1. Alves FM, Hirata IY, Gouvea IE, Alves MF, Meldal M, Brömme D, Juliano L and Juliano MA. 2007. Controlled peptide solvation in portion-mixing libraries of FRET peptides: improved specificity determination for Dengue 2 virus NS2B-NS3 protease and human cathepsin S. J Comb Chem 9: 627-634.
2. ′ subsite specificity of recombinant human cathepsin K and development of selective internally quenched fluorescent substrates. Biochem J 373: 981-986.
3. Alves MF, Araujo MC, Juliano MA, Oliveira EM, Krieger JE, Casarini DE, Juliano L and Carmona AK. 2005. A continuous fluorescent assay for the determination of plasma and tissue angiotensin I-convert-ing enzyme activity. Braz J Med Biol Res 38: 861-868.
4. Angelo PF, Lima AR, Alves FM, Blaber SI, Scarisbrick IA, Blaber M, Juliano L and Juliano MA. 2006. Substrate specificity of human kallikrein 6: salt and glycosaminoglycan activation effects. J Biol Chem 281: 3116-3126.
5. Araujo MC, Melo RL, Cezari MH, Juliano MA, Juliano L and Carmona AK. 2000. Peptidase speci-ficity characterization of C- and N-terminal catalytic sites of angiotensin I-converting enzyme. Biochemistry 39: 8519-8525.
6. Barros NM, Campos M, Bersanetti PA, Oliveira V, Juliano MA, Boileau G, Juliano L and Carmona AK. 2007. Neprilysin carboxydipeptidase speci-ficity studies and improvement in its detection with fluo-rescence energy transfer peptides. Biol Chem 388: 447-455.
7. Bersanetti PA, Andrade MC, Casarini DE, Juliano MA, Nchinda AT, Sturrock ED, Juliano L and CarmonaAK. 2004. Positional-scanningcombinatorial libraries of fluorescence resonance energy transfer peptides for defining substrate specificity of the angioten-sin I-converting enzyme and development of selective C-domain substrates. Biochemistry 43: 15729-15736.
8. ′ specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein. Bio-chem J 373: 271-279.
9. CarmelA and YaronA. 1978. An intramolecularly quen- ched fluorescent tripeptide as a fluorogenic substrate of angiotensin-I-converting enzyme and of bacterial dipeptidyl carboxypeptidase. Eur J Biochem 87: 265-273.
10. Carmona AK, Schwager SL, Juliano MA, Juliano L and Sturrock ED. 2006. A continuous fluores- cence resonance energy transfer angiotensin I-converting enzyme assay. Nat Protoc 1: 1971-1976.
11. Chagas JR, Juliano L and Prado ES. 1991. Intramolecularly quenched fluorogenic tetrapeptide substrates for tissue and plasma kallikreins. Anal Biochem 192: 419-425.
12. Chagas JR, Portaro FC, Hirata IY, Almeida PC, Juliano MA, Juliano L. and Prado ES. 1995. Determinants of the unusual cleavage specificity of lysylbradykinin-releasing kallikreins. Biochem J 306: 63-70.
13. Cotrin SS, Puzer L, de Souza Judice WA, Juliano L, Carmona AK. and Juliano MA. 2004. Positional- scanning combinatorial libraries of fluorescence resonance energy transfer peptides to define substrate specificity of carboxydipeptidases: assays with human cathepsin B. Anal Biochem 335: 244-252.
14. Cushman DW. and Cheung HS. 1971 Concentrations of angiotensin-converting enzyme in tissues of the rat. Biochim Biophys Acta 250: 261-265.
15. de Souza ES, Hirata IY, Juliano L. and Ito AS. 2000. End-to-end distance distribution in bradykinin observed by Förster resonance energy transfer. Biochim Biophys Acta 1474: 251-261.
16. Del Nery E, Chagas JR, Juliano MA, Prado ES. and Juliano L. 1995. Evaluation of the extent of the bind- ing site in human tissue kallikrein by synthetic substrates with sequences of human kininogen fragments. Biochem J 312: 233-239.
17. Del Nery E, Chagas JR, Juliano MA, Juliano L. and Prado ES. 1999. Comparison of human and porcine tissue kallikrein substrate specificities. Immunopharmacology 45: 151-157.
18. Dion N, Cohen P, Crine P. and Boileau G. 1997. Characterization of neprilysin (EC 3.4.24.11) S2′ subsite. FEBS Lett 411: 140-144.
19. Ehlers MR, Fox EA, Strydom DJ and Riordan JF. 1989. Molecular cloning of human testicular angiotensin- converting enzyme: the testis isoenzyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme. Proc Natl Acad Sci USA 86: 7741-7745.
20. Florentin D, Sassi A and Roques BP. 1984. A highly sensitive fluorometric assay for "enkephalinase", a neu- tral metalloendopeptidase that releases tyrosine-glycine-glycine from enkephalins. Anal Biochem 141: 62-69.
21. Foster T. 1948. Intermolecular energy migration and fluorescence. Ann Phys 2: 55-75.
22. Friedland J and Silverstein E. 1976. A sensitive fluorimetric assay for serum angiotensin converting enzyme. Am J Clin Pathol 66: 416-424.
23. Goudreau N, Guis C, Soleilhac JM and Roques BP. 1994. Dns-Gly-(p-NO2)Phe-beta Ala, a specific fluoro- genic substrate for neutral endopeptidase 24.11. Anal Biochem 219: 87-95.
24. Groisman GM and Meir A. 2003. CD10 is helpful in detecting occult or inconspicuous endometrial stromal cells in cases of presumptive endometriosis. Arch Pathol Lab Med 127: 1003-1006.
25. Hersh LB and Morihara K. 1986. Comparison of the subsite specificity of the mammalian neutral endopeptidase 24-11 (enkephalinase) to the bacterial neutral endopeptidase thermolysin. J Biol Chem 261: 6433-6437.
26. Hirata IY, Cesari MHS, Nakaie CR, Boshcov P, Ito AS, Juliano MA and Juliano L. 1994. Internally quenched fluorogenic protease substrates: Solid-phase synthesis and fluorescent spectroscopy of peptides containing ortho-aminobenzoyl-dinitrophenyl groups as donor-acceptor pairs. Lett Pept Sci 1: 299-301.
27. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ and Saido TC. 2001. Metabolic regulation of brain Abeta by neprilysin. Science 292: 1550-1552.
28. Jaspard E, Wei L and Alhenc-Gelas F. 1993. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 268: 9496-9503.
29. Johanning K, Juliano MA, Juliano L, Lazure C, Lamango NS, Steiner DF and Lindberg I. 1998. Specificity of prohormone convertase 2 on proenkephalin and proenkephalin-related substrates. J Biol Chem 273: 22672-22680.
30. Kerr MA and Kenny AJ.1974. Thepurificationandspecificity of a neutral endopeptidase from rabbit kidney brush border. Biochem J 137: 477-488.
31. Korkmaz B, Attucci S, Juliano MA, Kalupov T, Jourdan ML, Juliano L and Gautier F. 2008. Measuring elastase, proteinase 3 and cathepsin G activities at the surface of human neutrophils with fluorescence resonance energy transfer substrates. Nat Protoc 3: 1-9.
32. Letarte M, Vera S, Tran R, Addis JB, Onizuka RJ, Quackenbush EJ, Jongeneel CV and McInnes RR. 1988. Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase. J Exp Med 168: 1247-1253.
33. López-Otín C and Overall CM. 2002. Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol 3: 509-519.
34. Malfroy B and Burnier J. 1987. New substrates for enkephalinase (neutral endopeptidase) based on fluores- cence energy transfer. Biochem Biophys Res Commun 143: 58-66.
35. Malfroy B and Schwartz JC. 1982. Properties of enkephalinase from rat kidney: comparison of dipeptidylcarboxypeptidase and endopeptidase activities. Biochem Biophys Res Commun 106: 276-285.
36. Malfroy B and Schwartz JC. 1985. Comparison of dipeptidyl carboxypeptidase and endopeptidase activities in the three enkephalin-hydrolysing metallopeptidases: "angiotensin-converting enzyme", thermolysin and "enkephalinase". Biochem Biophys Res Commun 130: 372-378.
37. Medeiros MA, França MS, Boileau G, Juliano L and Carvalho KM. 1997. Specific fluorogenic substrates for neprylysin (neutral endopeptidase, EC 3.4.24.11) which are highly resistant to serine- and metalloproteases. Braz J Med Biol Res 30: 1157-1162.
38. Molinaro G, Rouleau JL and Adam A. 2002. Vasopeptidase inhibitors: a new class of dual zinc metallopeptidase inhibitors for cardiorenal therapeutics. Curr Opin Pharmacol 2: 131-141.
39. Molinaro G et al. 2005. Human recombinant membrane-bound aminopeptidase P: production of a soluble form and characterization using novel, internally quenched fluorescent substrates. Biochem J 385: 389-397.
40. Oliveira MC, Hirata IY, Chagas JR, Boschcov P, Gomes RSA, Figueiredo and Julaino L. 1992. Intramolecularly quenched fluorogenic peptide substrates for human renin. Anal Biochem 203: 39-46.
41. Pimenta DC, Chen VC, Chao J, Juliano MA and Juliano L. 2000. Alpha1-antichymotrypsin and kallis- tatin hydrolysis by human cathepsin D. J Protein Chem 19: 411-418.
42. Portaro FC, Cezari MH, Juliano MA, Juliano L and Prado ES. 1997. Design of kallidin-releasing tissue kallikrein inhibitors based on the specificities of the enzyme's binding subsites. Biochem J 323: 167-172.
43. ′ variations in extended substrates. Biochem J 347: 123-129.
44. Pryde et al. 2006. Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Synthesis and activity of functionalized glutaramides. J Med Chem 13: 4409-4424.
45. Puzer L, Cotrin SS, Alves MF, Egborge T, Araújo MS, Juliano MA, Juliano L, Brömme D and Carmona AK. 2004. Comparative substrate specificity analysis of recombinant human cathepsin V and cathepsin L. Arch Biochem Biophys 430: 274-283.
46. Puzer L, Cotrin SS, Cezari MH, Hirata IY, Julia-no MA, Stefe I, Turk D, Turk B, Juliano L and Carmona AK. 2005. Recombinant human cathepsin X is a carboxymonopeptidase only: a comparison with cathepsins B and L. Biol Chem 386: 1191-1195.
47. Réhault S, Brillard-Bourdet M, Juliano MA, Ju-liano L, Gauthier F and Moreau T. 1999. New, sensitive fluorogenic substrates for human cathepsin G based on the sequence of serpin-reactive site loops. J Biol Chem 274: 13810-13817.
48. Ronco P, Pollard H, Galceran M, Delauche M, Schwartz JC and Verroust P. 1988. Distribution of enkephalinase (membrane metalloendopeptidase, E.C. 3.4.24.11) in rat organs. Detection using a monoclonal antibody. Lab Invest 58: 210-217.
49. Roques BP, Noble F, Dauge V, Fournie-Zaluski MC and Beaumont A. 1993. Neutral Endopeptidase 24.11: structure,inhibitionandexperimentalandclinicalpharmacology. Pharmacol Rev 45: 87-146.
50. Rousseau A, Michaud A, Chauvet M-T, Lenfant M and Corvol P. 1995. The homoregulatory peptide N- acetyl-Ser-Asp-Pro is a natural and specific substrate of N-terminal active site of angiotensin converting enzyme. J Biol Chem 270: 3656-3661.
51. Sabatini RA, Bersanetti PA, Farias SL, Juliano L, Juliano MA, Casarini DE, Carmona AK, Paiva AC and Pesquero JB. 2007. Determination of angiotensin I-converting enzyme activity in cell culture us- ing fluorescence resonance energy transfer peptides. Anal Biochem 363: 255-262.
52. Sapsford KE, Berti L and Medintz IL. 2006. Materials for fluorescence resonance energy transfer analysis: beyond traditional donor-acceptor combinations. Angew Chem Int Edit 45: 4562-4589.
53. Schechter I and Berger A. 1967. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 27: 157-162.
54. Skeggs LT, Kahn JR and Shumway NP. 1956. The preparation and function of the hypertensin-converting enzyme. J Exp Med 103: 295-299.
55. Skidgel RA and Erdos EG. 1985. Novel activity of human angiotensin I converting enzyme: release of the NH2- and COOH-terminal tripeptides from the luteiniz- ing hormone-releasing hormone. Proc Natl Acad Sci USA 82: 1025-1029.
56. Skidgel RA, Engelbrecht S, Johnson AR and Erdos EG. 1984. HydrolysisofsubstancePandneurotensin by converting enzyme and neutral endopeptidase. Peptides 5: 769-776.
57. Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, Tregear G and Corvol P. 1988. Two putative active centers in human angiotensin I-converting enzyme. Proc Natl Acad Sci USA 85: 9386-9390.
58. Turk B. 2006. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5: 785-799.
59. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V and Turk B. 2007. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 13: 385-401.
60. Wei L, Alhenc-Gelas F, Soubrier F, Michaud A, Corvol P and Clauser E. 1991. Expression and characterization of recombinant human angiotensin I-converting enzyme. Evidence for a C-terminal transmembrane anchor and for a proteolytic processing of the secreted recombinant and plasma enzymes. J Biol Chem 266: 5540-5546.
61. Wei L, Clauser E, Alhenc-Gelas F and Corvol P. 1992. The two homologous domains of human angioten- sin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem 267: 13398-13405.
62. Welsch C, Grima M, Giesen EM, Helwig JJ, BarthelmebsM, CoquardC andImbsJL. 1989. Assay of tissue angiotensin converting enzyme. J Cardiovasc Pharmacol 4: S26-S31.
63. Whitworth JA. 2003. Emerging drugs in the management of hypertension. Expert Opin Emerg Drugs 8: 377-388.
64. Yang HYT, Erdös EG and Levin Y. 1970. A dipeptidyl carboxypeptidase that converts angiotensin I and inacti-vates bradykinin. Biochim Biophys Acta 214: 374-376.